Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2015
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancerShun Lu, Lu Li, Yi Luo, et al.
Thoracic Cancer|July 17, 2021
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trialJianhua Shi, Guimin Chen, Haitao Wang, et al.
Cancer Biology & Medicine|February 16, 2019
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatmentJing Wang, Yizhuo Zhao, Qiming Wang, et al.
Clinical Lung Cancer|January 20, 2016
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)Caicun Zhou, Yunchao Huang, Donglin Wang, et al.
JAMA Oncology|August 12, 2018
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical TrialBaohui Han, Kai Li, Qiming Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancerXiaoyan Si, Li Zhang, Hanping Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 19, 2012
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]Yan Huang, Yunpeng Liu, Jianying Zhou, et al.
Translational Lung Cancer Research|June 13, 2022
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 studyYizhuo Zhao, Qiming Wang, Li Zhang, et al.
Translational Lung Cancer Research|November 19, 2019
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trialLili Wang, Zhen He, Sen Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 9, 2019
Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung CancerJun Lu, Hua Zhong, Jun Wu, et al.
Pageof 8